Here are some apparently directional untied options trades that caught our attention in today’s trading:
Continue readingNO
Earlier we highlighted the implied move in the options market (along with a few other fun facts) for Amazon.com’s (AMZN) Q3 results due out after the close: The options market is predicting about a 7% …
Continue readingShares of Intel (INTC) made a new 52 week high last week following the companies positive pre-announcement for their current quarter: The company now expects third-quarter revenue to be $15.6 billion, plus or minus $300 …
Continue readingWill they? Won’t they? The financial press (and it seems the political press too) can’t stop with this. Yep, because it’s election season, everyone is playing the guessing game on a possible Fed rate hike …
Continue readingEvent: Autodesk (ADSK) reports their fiscal Q2 results tonight after the close. The options market is implying about a 6% one day post earnings move which is rich to its 4 qtr one day average move …
Continue readingIn my almost two decades in the market I am often amazed at how much leeway investors will give corporate managements that are obviously crooks, and how persistent some managements will be in their deceptive …
Continue readingEarlier in my MorningWord (Seeing the Forest For the Trees) I tried to explain why the relative out-performance in defensive stocks and sectors like U.S. telco, utilities, consumer staples and sectors like energy and materials (that …
Continue readingShares of JP Morgan have shown incredible relative strength to every major bank stock the world over, only down 19% from its 52 week highs and down about 14% in 2016. In the U.S., large …
Continue readingYesterday, I touched on the Dell/EMC mega deal that spans across computer hardware, services & software (A Shell Game of Declining Levered Assets). To sum up, the combination of these two companies in such a complicated …
Continue readingThis is the investment environment we live in. Celgene (CELG), a $98 billion market cap company that had $7.7 billion in sales in 2014, agrees to pay $7.3 billion for Receptos (RCPT), a biotech company …
Continue reading